Has Peter Nassar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $140,734 in general payments to Peter Nassar, MD across 356 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Nassar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Nassar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Nassar, MD

Pulmonary Disease · Jacksonville, FLNPI 1629157243

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $95,370 of the $140,734 with a category attached, or 67.8%. Jazz Pharmaceuticals Inc. accounts for 81.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $60,669, more than ten times the $382 reported in 2019. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$140,734in general payments, 2019–2025

Across 356 payments — averaging $395.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$114K
Inspire Medical Systems, Inc.$24K
Harmony Biosciences LLC$631
Avadel CNS Pharmaceuticals, LLC$476
Axsome Therapeutics, Inc.$411
Eisai Inc.$193
plus $1K from 12 others

What the payments were for

Consulting fees$18,18813%
Speaking & faculty fees$95,37068%
Travel & lodging$16,81712%
Food & beverage$9,9707%
Education$3890%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	204	$114,214
Inspire Medical Systems, Inc.	48	$23,779
Harmony Biosciences LLC	25	$631
Avadel CNS Pharmaceuticals, LLC	10	$476
Axsome Therapeutics, Inc.	17	$411
Eisai Inc.	15	$193
Fisher & Paykel Healthcare Inc	10	$170
Idorsia Pharmaceuticals US Inc	9	$155
Itamar Medical Inc	3	$127
Novo Nordisk	1	$121
Regeneron Healthcare Solutions, Inc.	1	$120
Amgen	1	$109
Merck	4	$69
Lilly USA, LLC	3	$64
Philips North America LLC	1	$32
Pfizer	2	$29
Resmed Corp	1	$20
Aytu Biopharma, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XYWAV$110,504
Inspire Upper Airway Stimulation System$22,546
Inspire$443
LUMRYZ$222
Wegovy$121
SUNOSI$121
DUPIXENT$120
Repatha$109
XYREM$108

How this compares

$140,734 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Medicare billing

Part B allowed, 2024

$123,159

Medicare patients

699

Services billed

1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Modafinil	22	$7,199
Armodafinil	24	$1,229
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	29	$918
Pramipexole DihydrochloridePramipexole Di-Hcl	51	$729
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	15	$585
Zolpidem Tartrate	48	$554
Ropinirole Hcl	17	$466
Quetiapine Fumarate	36	$414
Zolpidem Tartrate ErZolpidem Tartrate	13	$345
Trazodone Hcl	74	$323
Gabapentin	14	$202
Clonazepam	17	$188
Temazepam	12	$46

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Jacksonville

Jennifer FultonJacksonville$665K
Jose Soto SotoJacksonville$504K
Jorge MalleaJacksonville$457K
Abubakr BajwaJacksonville$414K
Bryan HustaJacksonville$283K
Sebastian Fernandez-BussyJacksonville$257K
Charles BurgerJacksonville$124K
Daniel WyzanJacksonville$100K
David Abia TrujilloJacksonville$68K
Franck RahaghiWeston$1.2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →